ADVFN US – Market Content Editor
-
Dragonfly Energy Shares Slide After Reverse Stock Split Plan Revealed
Shares of Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) sank nearly 44% in pre-market trading on Tuesday after the battery technology company announced it will carry out a 1-for-10 reverse stock split in order to remain compliant with Nasdaq listing requirements. The reverse split is scheduled to take effect on December 18, 2025, and will reduce the…
-
Autozi Shares Rally After $980 Million Procurement MOU Announcement
Shares of Autozi Internet Technology (NASDAQ:AZI) surged 39% in pre-market trading on Tuesday after the company revealed it had entered into a Memorandum of Understanding covering potential procurement arrangements valued at roughly $980 million. The non-binding MOU sets out plans for several buyers to leverage Autozi’s digital automotive e-commerce platform for centralized purchasing of complete…
-
Adagene Shares Jump After FDA Awards Fast Track Status to Cancer Treatment
Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the U.S. Food and Drug Administration has granted Fast Track Designation to its cancer therapy muzastotug when used in combination with Merck’s KEYTRUDA. The Fast Track designation covers the treatment of adult patients with microsatellite stable…
-
Humana Shares Slide Following Announcement of Insurance Leadership Changes
Shares of Humana Inc. (NYSE:HUM) dropped around 4% in pre-market trading on Tuesday after the healthcare insurer disclosed an upcoming leadership transition within its insurance division, even as it reiterated its full-year earnings outlook. The Louisville-based company said George Renaudin, President of the Insurance Segment, plans to retire by the third quarter of 2026 after…
-
Monte Rosa Shares Gain on Encouraging Prostate Cancer Trial Update
Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) climbed about 3.5% after the company released encouraging interim results from its Phase 1/2 clinical trial evaluating MRT-2359 alongside enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The clinical-stage biotech said patients with androgen receptor (AR) mutations achieved a 100% PSA response rate and a 100% disease control…
-
U.S. Job Growth Beats Forecasts in November as October Retail Spending Stalls
U.S. employment expanded more than economists anticipated in November, according to data released Tuesday by the Labor Department, pointing to resilience in the labor market despite recent volatility. Nonfarm payrolls rose by 64,000 last month, rebounding from a sharp decline of 105,000 jobs in October. The result exceeded expectations for an increase of around 50,000…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, U.S. Markets Seen Treading Water After Mixed Employment Signals
U.S. stock index futures pointed to a largely flat start on Tuesday, suggesting Wall Street could struggle to find clear direction after closing the previous session slightly lower following volatile trading. Investors appear cautious as they assess a mixed set of U.S. labor market figures, making it difficult to draw firm conclusions about the strength…
-
Wall Street Banks Wary as U.S. Markets Move Toward 24-Hour Stock Trading
U.S. equity markets are edging closer to round-the-clock trading, but enthusiasm across Wall Street is mixed, with several major banks taking a cautious stance toward the shift. While exchanges are moving ahead with plans for nearly continuous weekday trading as early as late next year, some of the largest U.S. banks remain hesitant to fully…
-
Smartphone Shipments Seen Falling in 2026 as Higher Chip Costs Weigh on Demand
Global smartphone shipments are expected to decline by 2.1% in 2026, as rising semiconductor costs begin to dampen consumer demand, according to a report released Tuesday by technology research firm Counterpoint. Electronics supply chains have recently been grappling with shortages of so-called legacy memory chips. Chipmakers have increasingly redirected capacity toward advanced memory used in…
-
Pfizer Sets Out 2026 Outlook, Signalling Softer Revenue and Earnings
Pfizer Inc. (NYSE:PFE) has released its financial outlook for 2026, forecasting revenue in a range of $59.5 billion to $62.5 billion and adjusted diluted earnings per share between $2.80 and $3.00. At the same time, the pharmaceutical group updated its guidance for 2025, now expecting revenue of about $62.0 billion, compared with its earlier forecast…